Endpoint Clinical RTSM vs Medidata RTSM(RTSM / IRT)
Sponsors and CROs choosing a randomization and trial supply management (RTSM, also called IRT) system for interventional trials.
Scope Sponsors and CROs choosing an RTSM/IRT system to randomize participants and manage investigational product supply in interventional trials. Site-side pharmacy tools and stand-alone supply planning software are out of scope.
These notes describe the products in the RTSM / IRT guide.
Endpoint Clinical RTSM
Best for
Sponsors who want an RTSM specialist with self-service study changes and central pharmacy workflows
What to consider
Endpoint Clinical is an RTSM specialist with two platforms: PULSE, with 20+ self-service modules, and the newer Elosity, which claims 2-6 week study setup and adds direct-to-patient shipping. Its Bluefin product adds supply forecasting. Public pages name few randomization methods, and the only named attestation is SOC 2 Type II.
Sponsors already on Rave EDC who want randomization and supply in the same system
What to consider
Medidata RTSM is unified with Rave EDC, so randomization and dispensing data do not need reconciling between two systems. Its fact sheets document block, stratified and dynamic allocation, supply forecasting, direct-to-patient shipping and post-go-live changes with little to no downtime. Pricing is not published.
Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.
Expand a feature definition or support note for context and its original source.
Endpoint Clinical RTSM vs Medidata RTSM (RTSM / IRT): category feature evidence and sources. Products are not ranked.
Category feature
Endpoint Clinical RTSM
Medidata RTSM
Randomization and blindingFeature definitions
Supported
Randomization or blinding workflows are stated.
Extended support
Named allocation methods include minimization or dynamic allocation.
Endpoint Clinical RTSM
Supported
Endpoint cites complex protocols, dosing strategies, adaptive designs and patient rollover, but its product pages do not name specific allocation methods.
Adaptive protocol support establishes base support; allocation methods are not named.
Medidata RTSM
Extended support
A Medidata fact sheet lists pre-validated permuted block and dynamic allocation, stratification, cohort management, titration and a randomization simulator (fact sheet dated May 2019).
Direct-to-patient delivery is stated alongside Bluefin supply forecasting.
Medidata RTSM
Extended support
The current fact sheet documents buffer and predictive supply schemes, forecasting that simulates future patient needs, direct-to-patient shipments and drug pooling across studies.
A study-setup timeline and version-tracked changes without interrupting live studies are stated.
Medidata RTSM
Supported
Medidata states a 2-3 week study build, and Edit Live Design allows post-go-live changes for protocol amendments (the 2024 fact sheet adds 'little to no downtime').
A build timeline and live amendments are stated, but little-to-no downtime permits some interruption.
Integrations and platformFeature definitions
Supported
Integration or data exchange with another system or application is described.
Extended support
Integration with a clinical-trial application plus an API for integration are both stated.
Endpoint Clinical RTSM
Extended support
Endpoint describes pre-built, API-based integrations with EDC, eCOA, eConsent and CTMS, but names no specific systems and has no EDC or eCOA of its own.
A SOC attestation establishes base security evidence; product-specific trial controls and public report access are not established.
Medidata RTSM
Supported
Medidata lists an ISO 27001:2022 certificate and a SOC 2+ Type II audit, and says its position statements cover 21 CFR Part 11 and EU Annex 11 (the statements sit behind a customer login).